top of page

NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM

Tucson, AZ, July 29, 2021 --( NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke.

Click here to read more

Recent Posts

See All

Tucson, AZ, May 16th, 2022 - NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of prepara

Tucson, AZ, May 9th, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases whe

bottom of page